
WHO tests pandemic response with Arctic ‘mammothpox' outbreak
Within weeks, ICUs were 'overwhelmed' and health systems were struggling to cope. Some countries introduced contact tracing and 'enforced quarantines,' while others took a more laissez-faire approach – and saw the 'uncontrolled spread' of a dangerous new disease.
This is the all-too-familiar scenario that ministers from 15 countries around the world were faced with last week when they gathered to test their readiness for the next pandemic.
The desktop exercise, led from the World Health Organisation's (WHO) headquarters in Geneva, was overseen by Dr Mike Ryan, the no-nonsense director of the agency's Health Emergencies Programme.
It simulated an outbreak of 'Mammothpox,' a deadly but fictional virus from the orthopox family, similar to smallpox (which killed an estimated half a billion people in the century before it was eradicated in 1980) and mpox, a dangerous variant of which is currently surging across central Africa.
The exercise documents, obtained by The Telegraph, give a rare insight into how the WHO and its member states might react and coordinate in the event of a new pandemic.
While the disease depicted was fictitious, the exercise was based on real science and imagines a paleontological dig for mammoths, sabretooth tigers, and other extinct creatures held in the permafrost going horribly wrong.
'Scientific research has demonstrated that ancient viruses can remain viable in permafrost for thousands of years,' says the WHO briefing document. 'The thawing of permafrost due to climate change has raised concerns about the potential release of pathogens previously unknown to modern medicine.'
The virus was potentially lethal and fast-moving, participating health officials were told.
'Mammothpox disease is severe, with a mortality intermediate between Mpox and Smallpox,' say the papers.
Smallpox killed about 30 per cent of those it infected before its eradication. Mpox is much less lethal but is currently exacting a terrible toll, especially on young children in Africa.
'With modest transmissibility and minimal asymptomatic spread it is controllable', they added, but only with 'effective coordinated responses – similar to SARS or Mpox'.
The assembled officials were all told that a 'multinational team of scientists' and a 'film crew' were behind the outbreak. They had travelled into the Arctic to find Mammoth remains being exposed by the retreating permafrost.
In a scene reminiscent of the opening of the film Jurassic Park, the team discovered a 'remarkably well-preserved' specimen and proceeded to thaw and analyse samples of its tissues on site.
They then returned to their respective countries, only to fall ill shortly after, 'presenting with symptoms of a pox-like illness'.
Among the participants in the two-day simulation were representatives from Denmark, Somalia, Qatar, Germany, Saudi Arabia, and Ukraine.
The United States and China did not take part.
Each country was given a 'small piece of the puzzle' to test how well they would share information and collaborate to contain the spread of the virus.
In an echo of the Covid pandemic, one country was told that a symptomatic Arctic researcher had boarded a cruise ship carrying 2,450 passengers and 980 crew.
The vessel effectively became a petri dish for scientists, who gathered data as the virus moved from cabin to cabin, allowing them to calculate the virus's reproduction or R number at between 1.6 and 2.3.
Qatar was told the virus was being spread through large social gatherings and in workplaces, while in Uganda all of its 22 cases were put down to 'household transmission'.
The desktop exercise was held over two days but simulated the first three weeks of the outbreak.
On the second day of the exercise, participants were told that progress in holding back the virus was being hampered by politics and divergent contaminants strategies between states.
Some countries implemented 'strict border controls, banned all international arrivals and restricted internal movement,' the document says. Others maintained 'open borders with minimal restrictions,' relying instead on 'contact tracing, isolation,and quarantine measures'.
During the Covid-19 pandemic, countries like Singapore, South Korea, New Zealand and Taiwan turned their ports and airports into a first-line of defence and tried to stop the virus from getting in altogether. But others, including Britain, were criticised for keeping their borders largely open.
Throughout the simulation, health officials from each of the participating countries joined Zoom calls to share details of how the outbreak was unfolding in their respective towns and cities and debate how to respond.
'Some of the countries were being very strict about border controls and in some cases very close neighbouring countries were being very loose, so on the calls we could have discussions around how we could harmonise those approaches,' said Dr Scott Dowell, a senior adviser at the WHO.
Dr Nedret Emiroglu, a director in the WHO's Health Emergencies Programme, said the mammothpox scenario was designed to be 'realistic with the ability to spread around the world'.
But the disease was also designed to be 'controllable if countries worked together,' she told The Telegraph.
While Exercise Polaris was playing out, negotiations on a new 'pandemic treaty' were continuing at the WHO.
After three years of arduous negotiations, including disagreements over plans for the distribution of drugs and vaccines, an agreement on the treaty could be reached as early as Tuesday, sources told The Telegraph.
While the countries involved in the mammothpox exercise were, ultimately, able to band together to contain the virus, a real outbreak would prove much more complicated, the WHO acknowledged.
The question of how to implement a vaccine strategy was not dealt with in the fictional dry run, for example, and the US – the WHO's biggest single funder – is about to leave the body.
Meanwhile, real digs continue in the Siberian permafrost, where the receding ice has sparked a gold rush for scientists and ivory hunters alike.
In 2023, Nasa researchers unfroze a 48,500-year-old 'zombie virus' found alongside frozen mammoth and wolf remains that would be lethal to humans.
And last month, the New York Times revealed that Siberian ivory hunters were scavenging for mammoth remains without concern or precaution for the ancient pathogens they might stumble across.
In total, there are thought to be over 10 million mammoths buried in the arctic permafrost.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Telegraph
14 hours ago
- Telegraph
World first as life-saving cancer drugs to be mixed at patients' bedsides
Cancer patients will get personalised drugs made at their bedside under new laws, The Telegraph can reveal. The UK is the first country in the world to relax the strict manufacturing rules that cause delays to time-sensitive treatments. An increasing number of new medicines, including for cancer and rare genetic disorders, involve creating a bespoke drug for each patient by collecting their cells and modifying them in a laboratory, before they are injected back into the patient. But because the samples have to be taken and edited in specialist facilities – often hundreds of miles away – patients are too often facing delays. They may become too unwell to receive the drug, or the medicine itself may not survive the journey because of its short shelf-life. From now, the last of these steps can be completed closer to the patient, reducing the time it takes to produce a life-saving treatment from months to just days, the medical regulator said. 'Flexible, responsive system' The new laws, introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), will mean the drugs can be manufactured where the patient is – and given to them in hospital or their own homes. Writing in The Telegraph, Lawrence Tallon, the new chief executive of the MHRA, said it was about creating 'a more flexible, responsive system that meets the needs of modern medicine' rather than forcing 'the medicine to fit an outdated system'. 'Some of these advanced therapies are made using a person's own cells. Others are built around their genetic code. A few are so sensitive they can't be frozen or stored – they have to be given to the patient within mere minutes of being made. That's a world away from how medicines are typically mass-made and distributed today,' he said. 'In these cases, delays can be critical. Some patients have become too unwell to receive their treatment in time. In others, the medicine simply didn't survive the journey.' He added: 'Hospitals can now carry out the final steps of manufacturing on-site – under the same strict standards, but far more quickly. 'That means a cancer patient could now have their immune cells collected, modified, and returned at the same hospital. A child with a rare genetic disorder can receive a therapy made at their bedside.' 'Personalised therapies' Mobile units will also be deployed to finish the manufacturing of the drugs for patients who are too sick to leave their homes or need to limit hospital visits because of weakened immune systems. The MHRA said the move mirrored how chemotherapy and antibiotics are prepared locally, but stressed that there would still be strict safeguards and regulatory protocols. There will also be a 'central control site' that will oversee the personalised therapies being completed in hospitals. Wes Streeting, the Health Secretary, said it was a 'game-changer'. 'Cancer treatments tailored in days, not months. Life-saving therapies made at your bedside, not hundreds of miles away,' he said. 'Our Plan for Change promised to build an NHS fit for the future. Today we're delivering on that pledge by bringing cutting-edge care directly to patients when they need it most. 'This type of therapy means patients can be treated and return home more quickly.' One example of a personalised treatment that is set to become more accessible for patients is CAR-T cancer therapy. It involves genetically modifying a blood cancer patients' immune cells so that the immune system recognises and kills the cancer cells that would otherwise go undetected by the body and continue to spread. Previously, hospitals were only able to offer these treatments through complicated, one-off arrangements. The changes have already come into effect after the legislation, known as The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025, was passed last month. It covers a range of innovations, including cell and gene therapies, tissue-engineered treatments, 3D printed products, blood products, and medicinal gases. Lord Vallance, the science minister and Government's former chief scientific officer, said the 'world-first framework gives the NHS and innovators a clear, safe way to bring advanced treatments from the lab to the patient's bedside'. 'It's a powerful example of how smart regulation can help more patients benefit from the best of British science.' 'Modern medicine needs a modern delivery system' By Lawrence Tallon For most medicines, the system works well enough. Medicines are made in bulk, boxed up, and shipped off to where they're needed in the world. It's how care has been delivered for decades. But a new generation of personalised therapies is beginning to challenge that model – and unless we adapt, patients could miss out. Some of these advanced therapies are made using a person's own cells. Others are built around their genetic code. A few are so sensitive they can't be frozen or stored – they have to be given to the patient within mere minutes of being made. That's a world away from how medicines are typically mass-made and distributed today. In these cases, delays can be critical. Some patients have become too unwell to receive their treatment in time. In others, the medicine simply didn't survive the journey. We need a more flexible, responsive system that meets the needs of modern medicine, not force the medicine to fit an outdated system. That's why this week, the UK became the first country in the world to introduce a new legal framework that allows these advanced medicines to be made at the point of care. Under new regulations introduced by the Medicines and Healthcare products Regulatory Agency (MHRA), hospitals can now carry out the final steps of manufacturing on-site – under the same strict standards, but far more quickly. That means a cancer patient could now have their immune cells collected, modified and returned at the same hospital. A child with a rare genetic disorder can receive a therapy made at their bedside. No more shipping cells hundreds of miles away and hoping they survive the journey back. It also offers a safer alternative for people too unwell to travel, or whose immune systems make hospital visits risky. 'Supporting early access to promising treatments' This is part of a wider effort to modernise the way we support innovation in the UK. We've shortened the time it takes to approve clinical trials to 40 days. We've introduced new routes for authorising medicines already approved by trusted international regulators. And where the evidence is strong and the need is urgent, we support early access to promising treatments. We're paying particular attention to rare diseases, where patients often face the longest waits for new treatments. While each condition may affect only a few people, the overall impact is large: around 3.5 million people in the UK, and an estimated 300 million globally, live with a rare condition. Yet developing treatments is often more difficult, with fewer clinical trial participants and less commercial return. That's why we're offering targeted support. For companies working on rare disease therapies, we've reduced or waived fees and increased access to expert scientific advice. The aim is to make it simpler and more affordable to bring forward safe treatments where there is high need and few other options. We're also supporting smarter ways to generate evidence. For very rare conditions, large-scale trials aren't always possible. We're working with researchers to use high-quality real-world data, like NHS records and patient registries, so that safe and effective treatments aren't held back for lack of traditional trial data. Medical innovation doesn't end with discovery or what's in the vial. It's also about tackling the barriers that stop new treatments reaching patients. That means creating a safe system built for tomorrow's medicines – especially for people with the fewest options – whether by changing how they're approved, how trials are run, or how evidence is gathered. After all, a life-changing treatment only matters because we can deliver it when and where the person needs it.


Telegraph
17 hours ago
- Telegraph
China may be looking to draw a new ‘Nine Dash Line' in the Arctic
Once China begins operating in a stretch of sea, reclaiming it often proves an uphill battle – just ask the Philippines or the Vietnamese or anyone else entangled in Beijing's unyielding 'Nine Dash Line' campaign to snatch the South China Sea. Now that same playbook seems to be unfolding in the frozen expanses of the Arctic, where China's polar icebreaker Xue Long 2 has been spotted in international waters north of Alaska, signalling a continued push into the High North that could reshape global maritime dynamics. Xue Long 2, China's first domestically constructed polar vessel, left from Shanghai for its summer 2025 research expedition and crossed into Arctic territory around July 22. Designed to be able to break through ice up to 1.5 metres thick, the ship has been conducting operations in sensitive areas, with indications that two more Chinese icebreakers are en route to join the effort. There's a pattern here. China stakes out a presence – ostensibly scientific, often co-operative. Then comes more equipment. Then military protection. Then grey-zone harassment. Eventually, the region becomes 'disputed', often indefinitely. The Arctic, long considered neutral ground, could well be the next frontier in this silent creeping strategy.

South Wales Argus
a day ago
- South Wales Argus
Monmouthshire joins WHO age-friendly communities network
The county is now part of the World Health Organisation's (WHO) Global Network for Age-friendly Cities and Communities, a programme established in 2010 that supports cities and communities in becoming better places to grow older. This follows a council decision in January to pursue Age-Friendly County status, supported by a survey of residents aged 50 and over. The survey gathered feedback to inform the council's efforts and highlighted areas for improvement and success. Monmouthshire County Council's cabinet member for social care, safeguarding and accessible health services said: "This is a significant step in our journey to ensure that Monmouthshire is a county where our older adults can live comfortably, participate fully in civic life, and continue to contribute meaningfully. "Building on our extensive consultation with older residents, we will continue to ensure that the voices of older people are at the centre of our efforts to create a more age-friendly county." Monmouthshire's membership is the result of collaborative work with residents, businesses, third-sector organisations, and statutory partners. Councillor Jackie Strong, Monmouthshire's older people's champion, said: "By becoming a member, we can learn from communities from around the world about their efforts to create age-friendly environments. "I look forward to learning from these communities and sharing the work already happening in our communities every day." The WHO network connects cities and communities around the world that are committed to supporting healthy ageing and improving quality of life for older adults.